Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic

Roberta Ara1, Rachid Rafia, Sue E Ward

  • 1School of Health & Related Research, University of Sheffield, Regent Court, Sheffield S1 4DA, UK. r.m.ara@sheffield.ac.uk

Insights

Intensive lipid-lowering therapy is cost-effective for acute coronary syndrome patients compared to standard statins. Atorvastatin 80 mg/day is optimal post-patent expiry, while simvastatin 80 mg/day is not recommended.

Area of Science:

  • Cardiovascular Medicine
  • Health Economics
  • Pharmacoeconomics

Background:

  • Acute coronary syndrome (ACS) necessitates effective and economical long-term management strategies.
  • Lipid-lowering therapies are crucial in managing ACS, with varying cost-effectiveness profiles.
  • Identifying optimal treatment regimens balances clinical outcomes with economic considerations.

Purpose of the Study:

  • To review the literature on the cost-effectiveness of intensive lipid-lowering regimens versus generic low-dose statins in ACS patients.
  • To compare the economic value of different statin treatment intensities for secondary prevention post-ACS.
  • To determine the most cost-effective statin therapy based on projected long-term outcomes and costs.

Main Methods:

  • A literature review was performed to identify relevant cost-effectiveness studies.
  • Included studies utilized Markov models to simulate long-term clinical pathways and costs.
  • Studies were analyzed for differences in effectiveness data, health state definitions, and predicted events.

Main Results:

  • All reviewed studies concluded that intensive lipid-lowering regimens are cost-effective compared to generic low-dose statins for ACS.
  • Significant variations existed in effectiveness data, health state definitions, and event predictions across studies.
  • Atorvastatin 80 mg/day is projected as the most optimal treatment if its annual cost decreases to GBP 90 post-patent expiry.

Conclusions:

  • Intensive lipid-lowering therapy offers a cost-effective strategy for managing patients with acute coronary syndrome.
  • Atorvastatin 80 mg/day emerges as the preferred optimal treatment option for ACS patients following patent expiry, given its favorable cost-effectiveness.
  • Simvastatin 80 mg/day is not recommended due to safety concerns and limited additional benefits compared to intensive regimens.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...